Foghorn Therapeutics Inc.
FHTXNasdaqCIK 1822462HealthcareFiscal year ends Dec 31
Reports and events: 130 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2022-03-1007:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-22-005644 |
| 2022-01-1007:03 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001628280-22-000561 |
| 2021-12-2116:10 ET | 8-K | 1.02 Termination of a material agreement | 0001628280-21-025476 |
| 2021-12-1306:04 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-21-024887 |
| 2021-11-0916:23 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001628280-21-022556 |
| 2021-11-0907:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-21-022395 |
| 2021-09-0107:09 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-21-017921 |
| 2021-08-2307:18 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-21-017463 |
| 2021-08-1016:24 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001628280-21-016418 |
| 2021-08-1007:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-21-016332 |
| 2021-07-1408:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-21-013802 |
| 2021-07-0916:16 ET | 8-K | 5.07 Shareholder vote results | 0001628280-21-013692 |
| 2021-06-1507:30 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-21-012216 |
| 2021-06-0116:29 ET | DEF 14A | Proxy statementPeriod 2021-07-08 | 0001193125-21-178596 |
| 2021-06-0107:09 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-21-011392 |
| 2021-05-1116:05 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001628280-21-009813 |
| 2021-04-2916:14 ET | 10-K/A | Annual report, amendedPeriod 2020-12-31 | 0001193125-21-140447 |
| 2021-04-2816:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-136817 |
| 2021-03-2316:02 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-091154 |
| 2021-03-1816:02 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001193125-21-085777 |
| 2021-03-1808:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-21-085075 |
| 2021-02-1608:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-21-043468 |
| 2020-12-0416:51 ET | 10-Q | Quarterly reportPeriod 2020-09-30 | 0001193125-20-310715 |
| 2020-12-0416:47 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-20-310711 |
| 2020-11-2516:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-20-303604 |
| 2020-10-2917:00 ET | SC 13D | Ownership report, active investor | 0001193125-20-281152 |
| 2020-10-2717:00 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-20-278568 |
| 2020-10-2209:47 ET | S-1/A | Registration statement, amended | 0001193125-20-274108 |
| 2020-10-1906:06 ET | S-1/A | Registration statement, amended | 0001193125-20-271564 |
| 2020-10-0216:03 ET | S-1 | Registration statement | 0001193125-20-262469 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 9, 2026, 17:27 ET. Listed shows no prices and gives no investment advice.